INMB - Hypotheses Underlying Alzheimer's Drug Development
- Oxidative stress contributes to the formation of misfolded amyloid and tau proteins and to neuroinflammation all of which can further increase oxidative stress.
- Drugs that target pro-inflammatory cytokines such as INmune Bio's XPro1595 and Montelukast are likely too specific and too late in the process to have much effect on Alzheimer's disease.
- Alector's AL002 by increasing the activity of TREM2 stimulates beneficial immune responses while blocking neurotoxic inflammation; however the pathway by which this happens is damaged by nitration in Alzheimer's disease.
- Antioxidant drug candidates such as Anavex's blarcamesine and Cyclo Therapeutics Trappsol Cyclo and natural products such as panax ginseng are more likely to provide effective treatments for Alzheimer's disease.
For further details see:
Hypotheses Underlying Alzheimer's Drug Development